Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women
Abstract Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence supplement clinical data to support dosing...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | CPT: Pharmacometrics & Systems Pharmacology |
| Online Access: | https://doi.org/10.1002/psp4.13251 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846162176285343744 |
|---|---|
| author | Jia Ning Amita Pansari Karen Rowland Yeo Aki T. Heikkinen Catriona Waitt Lisa M. Almond |
| author_facet | Jia Ning Amita Pansari Karen Rowland Yeo Aki T. Heikkinen Catriona Waitt Lisa M. Almond |
| author_sort | Jia Ning |
| collection | DOAJ |
| description | Abstract Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence supplement clinical data to support dosing decisions. A PBPK model for the antiretroviral dolutegravir (mainly metabolized by UGT1A1) was verified using reported exposures in non‐pregnant healthy volunteers, pregnant women, and the umbilical cord, lactating mothers, and breastfed neonates. The model was then applied to predict the impact of UGT1A1 phenotypes in extensive (EM), poor (PM), and ultra‐rapid metabolizers (UM). The predicted dolutegravir maternal plasma and umbilical cord AUC in UGT1A1 PMs was 1.6‐fold higher than in EMs. The predicted dolutegravir maternal plasma and umbilical cord AUC in UGT1A1 UMs mothers was 1.3‐fold lower than in EMs. The predicted mean systemic and umbilical vein concentrations were in excess of the dolutegravir IC90 at 17, 28, and 40 gestational weeks, regardless of UGT1A1 phenotype, indicating that the standard dose of dolutegravir (50 mg q.d., fed state) is generally appropriate in late pregnancy, across UGT1A1 phenotypes. Applying the model in breastfed infants, a 1.5‐, 1.7‐, and 2.2‐fold higher exposure in 2‐day‐old neonates, 10‐day‐old neonates, and infants who were UGT1A1 PMs, respectively, compared with EMs of the same age. However, it should be noted that the exposure in breastfed infants who were UGT1A1 PMs was still an order of magnitude lower than maternal exposure with a relative infant daily dose of <2%, suggesting safe use of dolutegravir in breastfeeding women. |
| format | Article |
| id | doaj-art-6817e79f49384dab86ed83445977bcd4 |
| institution | Kabale University |
| issn | 2163-8306 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | CPT: Pharmacometrics & Systems Pharmacology |
| spelling | doaj-art-6817e79f49384dab86ed83445977bcd42024-11-20T17:18:44ZengWileyCPT: Pharmacometrics & Systems Pharmacology2163-83062024-11-0113111924193810.1002/psp4.13251Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating womenJia Ning0Amita Pansari1Karen Rowland Yeo2Aki T. Heikkinen3Catriona Waitt4Lisa M. Almond5Certara Predictive Technologies Division Sheffield UKCertara Predictive Technologies Division Sheffield UKCertara Predictive Technologies Division Sheffield UKCertara Predictive Technologies Division Sheffield UKDepartment of Pharmacology and Therapeutics University of Liverpool Liverpool UKCertara Predictive Technologies Division Sheffield UKAbstract Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence supplement clinical data to support dosing decisions. A PBPK model for the antiretroviral dolutegravir (mainly metabolized by UGT1A1) was verified using reported exposures in non‐pregnant healthy volunteers, pregnant women, and the umbilical cord, lactating mothers, and breastfed neonates. The model was then applied to predict the impact of UGT1A1 phenotypes in extensive (EM), poor (PM), and ultra‐rapid metabolizers (UM). The predicted dolutegravir maternal plasma and umbilical cord AUC in UGT1A1 PMs was 1.6‐fold higher than in EMs. The predicted dolutegravir maternal plasma and umbilical cord AUC in UGT1A1 UMs mothers was 1.3‐fold lower than in EMs. The predicted mean systemic and umbilical vein concentrations were in excess of the dolutegravir IC90 at 17, 28, and 40 gestational weeks, regardless of UGT1A1 phenotype, indicating that the standard dose of dolutegravir (50 mg q.d., fed state) is generally appropriate in late pregnancy, across UGT1A1 phenotypes. Applying the model in breastfed infants, a 1.5‐, 1.7‐, and 2.2‐fold higher exposure in 2‐day‐old neonates, 10‐day‐old neonates, and infants who were UGT1A1 PMs, respectively, compared with EMs of the same age. However, it should be noted that the exposure in breastfed infants who were UGT1A1 PMs was still an order of magnitude lower than maternal exposure with a relative infant daily dose of <2%, suggesting safe use of dolutegravir in breastfeeding women.https://doi.org/10.1002/psp4.13251 |
| spellingShingle | Jia Ning Amita Pansari Karen Rowland Yeo Aki T. Heikkinen Catriona Waitt Lisa M. Almond Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women CPT: Pharmacometrics & Systems Pharmacology |
| title | Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women |
| title_full | Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women |
| title_fullStr | Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women |
| title_full_unstemmed | Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women |
| title_short | Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women |
| title_sort | using pbpk modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women |
| url | https://doi.org/10.1002/psp4.13251 |
| work_keys_str_mv | AT jianing usingpbpkmodelingtosupplementclinicaldataandsupportthesafeandeffectiveuseofdolutegravirinpregnantandlactatingwomen AT amitapansari usingpbpkmodelingtosupplementclinicaldataandsupportthesafeandeffectiveuseofdolutegravirinpregnantandlactatingwomen AT karenrowlandyeo usingpbpkmodelingtosupplementclinicaldataandsupportthesafeandeffectiveuseofdolutegravirinpregnantandlactatingwomen AT akitheikkinen usingpbpkmodelingtosupplementclinicaldataandsupportthesafeandeffectiveuseofdolutegravirinpregnantandlactatingwomen AT catrionawaitt usingpbpkmodelingtosupplementclinicaldataandsupportthesafeandeffectiveuseofdolutegravirinpregnantandlactatingwomen AT lisamalmond usingpbpkmodelingtosupplementclinicaldataandsupportthesafeandeffectiveuseofdolutegravirinpregnantandlactatingwomen |